Harvard-MIT Division of Health Sciences & Technology, Cambridge, Massachusetts, USA.
Nat Biotechnol. 2011 Mar;29(3):273-7. doi: 10.1038/nbt.1780. Epub 2011 Feb 13.
Molecular biomarkers can be used as objective indicators of pathologic processes. Although their levels often change over time, their measurement is often constrained to a single time point. Cumulative biomarker exposure would provide a fundamentally different kind of measurement to what is available in the clinic. Magnetic resonance relaxometry can be used to noninvasively monitor changes in the relaxation properties of antibody-coated magnetic particles when they aggregate upon exposure to a biomarker of interest. We used implantable devices containing such sensors to continuously profile changes in three clinically relevant cardiac biomarkers at physiological levels for up to 72 h. Sensor response differed between experimental and control groups in a mouse model of myocardial infarction and correlated with infarct size. Our prototype for a biomarker monitoring device also detected doxorubicin-induced cardiotoxicity and can be adapted to detect other molecular biomarkers with a sensitivity as low as the pg/ml range.
分子生物标志物可用作病理过程的客观指标。虽然它们的水平通常随时间变化，但它们的测量通常局限于单个时间点。累积生物标志物暴露将提供一种与临床中可用的测量方法完全不同的测量方法。磁共振弛豫测量法可用于非侵入性地监测当抗体包被的磁性颗粒在暴露于感兴趣的生物标志物时聚集时，其弛豫特性的变化。我们使用含有这种传感器的植入式设备，在生理水平上连续监测三种临床相关心脏生物标志物长达 72 小时的变化。在心肌梗死的小鼠模型中，实验组和对照组之间的传感器反应存在差异，并且与梗死面积相关。我们的生物标志物监测设备原型还检测到多柔比星诱导的心脏毒性，并且可以进行适应性改造，以检测其他分子生物标志物，其灵敏度低至 pg/ml 范围。
